VentiRx Pharmaceuticals Granted Orphan Drug Designation in the European Union For Motolimod in the Treatment of Ovarian Cancer
April 27, 2015The European Commission grants orphan designation to VentiRx's motolimod for the treatment of ovarian cancer. Motolimod was granted orphan drug designation by the U.S. FDA in April 2014.
More »
aTyr Pharma Receives U.S. FDA Orphan Designation for ResolarisTM
April 27, 2015aTyr Pharma's investigational new drug Resolaris has been granted Orphan Drug Designation by the U.S. FDA for the treatment of facioscapulohumeral muscular dystrophy (FSHD)
More »
Celator® Pharmaceuticals Presents Data at the American Association for Cancer Research Annual Meeting
April 22, 2015Celator presented data for CPX-351, its lead product candidate, at AACR in Philadelphia on April 18-22. The data presented described the effects of combining CPX-351 with traditional chemotherapy and novel molecularly targeted agents to treat AML and othe
More »